InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,828.00
(
0.95%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
86.78
(
0.00%
)
Bitcoin
56,316.56
(
-0.59%
)
Post# of 252494
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

flatlander_60048

Send PM Follow Ignore
Followers 10
Posts 477
Boards Moderated 0
Alias Born 02/10/2006

flatlander_60048

Re: DewDiligence post# 252468

Wednesday, 07/03/2024 11:53:07 AM

Wednesday, July 03, 2024 11:53:07 AM

Post# of 252494
The PBM issue also significantly reduces the price savings that were contemplated due to biosimilar competition. Sandoz was able to capture 37% of the biosimilar humira market when they negotiated with CVS to have the Sandoz product named to the CVS formulary list. Sandoz now jointly markets their product "Humiroz" with Cordavis (the CVS in store brand) but I haven't heard them discuss the royalty or payment % given back to CVS. Sandoz has said this system is the reason that the US will never realize the EU level of savings from biosimilars.

https://www.forbes.com/sites/joshuacohen/2024/05/02/cvs-caremarks-policy-shift-on-humira-biosimilars-may-not-be-what-the-doctor-ordered/

FL
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up